198 related articles for article (PubMed ID: 27021744)
1. Challenges in Using MCDA for Reimbursement Decisions on New Medicines?
Walker A
Value Health; 2016; 19(2):123-4. PubMed ID: 27021744
[No Abstract] [Full Text] [Related]
2. Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force.
Marsh K; IJzerman M; Thokala P; Baltussen R; Boysen M; Kaló Z; Lönngren T; Mussen F; Peacock S; Watkins J; Devlin N;
Value Health; 2016; 19(2):125-37. PubMed ID: 27021745
[TBL] [Abstract][Full Text] [Related]
3. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
[TBL] [Abstract][Full Text] [Related]
4. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales.
Birch S; Gafni A
Health Econ; 2002 Apr; 11(3):185-91. PubMed ID: 11921316
[No Abstract] [Full Text] [Related]
5. Valued lives: Britain stirs outcry by weighing benefits of drugs versus price; government arm finds pills for Alzheimer's too costly, angering patients, Pfizer.
Whalen J
Wall St J (East Ed); 2005 Nov; ():A1, A11. PubMed ID: 16502534
[No Abstract] [Full Text] [Related]
6. Twenty years of using economic evaluations for drug reimbursement decisions: what has been achieved?
Drummond M
J Health Polit Policy Law; 2013 Dec; 38(6):1081-102. PubMed ID: 23974475
[TBL] [Abstract][Full Text] [Related]
7. Medical necessity: trying to reach consensus.
Phillips L
Hosp Technol Ser; 1996 May; 15(6):5, 10. PubMed ID: 10158519
[No Abstract] [Full Text] [Related]
8. How NICE may be outflanked.
Ferner RE; McDowell SE
BMJ; 2006 May; 332(7552):1268-71. PubMed ID: 16735342
[No Abstract] [Full Text] [Related]
9. Saying no isn't NICE - the travails of Britain's National Institute for Health and Clinical Excellence.
Steinbrook R
N Engl J Med; 2008 Nov; 359(19):1977-81. PubMed ID: 18987366
[No Abstract] [Full Text] [Related]
10. Addressing the challenge for well informed and consistent reimbursement decisions: the case for reference models.
Haji Ali Afzali H; Karnon J
Pharmacoeconomics; 2011 Oct; 29(10):823-5. PubMed ID: 21770483
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness considerations at NICE.
Rawlins M; Dillon A
Lancet; 2008 Oct; 372(9646):1302. PubMed ID: 18929903
[No Abstract] [Full Text] [Related]
12. Why orphan drug coverage reimbursement decision-making needs patient and public involvement.
Douglas CM; Wilcox E; Burgess M; Lynd LD
Health Policy; 2015 May; 119(5):588-96. PubMed ID: 25641123
[TBL] [Abstract][Full Text] [Related]
13. Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force.
Thokala P; Devlin N; Marsh K; Baltussen R; Boysen M; Kalo Z; Longrenn T; Mussen F; Peacock S; Watkins J; Ijzerman M
Value Health; 2016 Jan; 19(1):1-13. PubMed ID: 26797229
[TBL] [Abstract][Full Text] [Related]
14. Review of NICE's recommendations, 1999-2005.
Raftery J
BMJ; 2006 May; 332(7552):1266-8. PubMed ID: 16735341
[No Abstract] [Full Text] [Related]
15. What kind of health economics do we need?
Lhachimi SK; Ostermann H
Z Evid Fortbild Qual Gesundhwes; 2016; 110-111():18-20. PubMed ID: 26875030
[No Abstract] [Full Text] [Related]
16. Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?
Oliva-Moreno J; Puig-Junoy J; Trapero-Bertran M; Epstein D; Pinyol C; Sacristán JA
Value Health; 2020 Jan; 23(1):25-31. PubMed ID: 31952669
[TBL] [Abstract][Full Text] [Related]
17. Dutch doctors call for EU evaluation of cost effectiveness of high cost orphan drugs.
Sheldon T
BMJ; 2012 Aug; 345():e5461. PubMed ID: 22890124
[No Abstract] [Full Text] [Related]
18. Prognosis without treatment as a modifier in health economic assessments.
Camidge R; Walker A; Oliver JJ; Nussey F; Maxwell S; Jodrell D; Webb DJ
BMJ; 2005 Jun; 330(7504):1382-4. PubMed ID: 15947403
[TBL] [Abstract][Full Text] [Related]
19. The Challenge of Conditional Reimbursement: Stopping Reimbursement Can Be More Difficult Than Not Starting in the First Place!
van de Wetering EJ; van Exel J; Brouwer WB
Value Health; 2017 Jan; 20(1):118-125. PubMed ID: 28212952
[TBL] [Abstract][Full Text] [Related]
20. Limits on use of health economic assessments for rare diseases.
Hyry HI; Stern AD; Cox TM; Roos JC
QJM; 2014 Mar; 107(3):241-5. PubMed ID: 24453281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
